MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Ocular Therapeutix Inc

Cerrado

SectorSalud

7.3 11.11

Resumen

Variación precio

24h

Actual

Mínimo

6.41

Máximo

7.3

Métricas clave

By Trading Economics

Ingresos

-12M

-48M

Ventas

1.7M

17M

BPA

-0.29

Margen de beneficio

-283.269

Empleados

274

EBITDA

-12M

-44M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+170.18% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

276M

1.2B

Apertura anterior

-3.81

Cierre anterior

7.3

Noticias sobre sentimiento de mercado

By Acuity

62%

38%

339 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Ocular Therapeutix Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 abr 2025, 23:55 UTC

Acciones populares

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 abr 2025, 22:50 UTC

Principales Movimientos del Mercado

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 abr 2025, 21:08 UTC

Ganancias

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 abr 2025, 21:00 UTC

Ganancias

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 abr 2025, 23:56 UTC

Charlas de Mercado

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 abr 2025, 23:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 abr 2025, 23:44 UTC

Charlas de Mercado

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 abr 2025, 23:44 UTC

Principales Noticias

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 abr 2025, 23:32 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 23:32 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 abr 2025, 23:32 UTC

Charlas de Mercado

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 abr 2025, 23:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 abr 2025, 23:12 UTC

Charlas de Mercado

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 abr 2025, 23:10 UTC

Charlas de Mercado

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 abr 2025, 23:09 UTC

Charlas de Mercado

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 abr 2025, 23:09 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 22:57 UTC

Charlas de Mercado

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 abr 2025, 22:56 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 22:56 UTC

Charlas de Mercado

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 abr 2025, 22:43 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 abr 2025, 22:12 UTC

Charlas de Mercado

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 abr 2025, 21:48 UTC

Principales Noticias

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 abr 2025, 21:41 UTC

Charlas de Mercado

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 abr 2025, 21:17 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 21:17 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 abr 2025, 21:17 UTC

Charlas de Mercado

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 abr 2025, 21:04 UTC

Principales Noticias

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 abr 2025, 21:03 UTC

Charlas de Mercado

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 abr 2025, 20:53 UTC

Ganancias

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 abr 2025, 20:52 UTC

Ganancias

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparación entre iguales

Cambio de precio

Ocular Therapeutix Inc Esperado

Precio Objetivo

By TipRanks

170.18% repunte

Estimación a 12 meses

Media 17.67 USD  170.18%

Máximo 22 USD

Mínimo 14 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocular Therapeutix Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

9

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 7.81Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

339 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.